Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Elevated pulmonary arterial systolic pressure is strongly associated with mortality in patients with sickle cell disease (SCD). A tricuspid regurgitant velocity (TRV) of 2.5 m/s or greater by trans-thoracic echocardiogram is a key marker of risk [1–3]. The pathophysiologic mechanism involves release from the red cell during intravascular hemolysis of cell-free plasma hemoglobin and arginase [4]. Hydroxyurea is the only drug approved by the Food and Drug Administrations specifically for SCD. It acts by increasing levels of fetal hemoglobin, which inhibits sickling, and has been shown to reduce the incidence of vaso-occlusive crisis (VOC), and prolong survival in patients with sickle cell disease [5,6]. Because fetal hemoglobin also reduces the rate of hemolysis in SCD, hypothetically, hydroxyurea might also reduce the severity of hemolysis-linked vascular dysfunction and pulmonary hypertension. Herein, we describe five patients with sickle cell disease having elevated pulmonary arterial systolic pressure who exhibited improvement in their baseline laboratory parameters of hemolysis, accompanied by reduced TRV, during treatment with hydroxyurea. Hydroxyurea may have a role in the management of selected patients with elevated TRV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035477 · Cited by 1,325
Kato, G. J., Gladwin, M. T., & Steinberg, M. H. (2007) · Blood Reviews · doi:10.1016/j.blre.2006.07.001 · Cited by 876 · cited 2×
“The pathophysiology of SCD is multifactorial, with components of vaso-occlusion due to decreased erythrocyte compliance, abnormal endothelial adhesion, and hemolysis-linked endothelial dysfunction promoting proliferative vasculopathy [4].”
BackgroundSelf-citationKato, G. J., McGowan, V., Machado, R. F., Little, J. A., Taylor, J., Morris, C. R., Nichols, J. S., Wang, X., Poljakovic, M., Morris, S. M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2373 · Cited by 661
Self-citationPulmonary hypertension in patients with sickle cell disease: a longitudinal study
Ataga, K. I., Moore, C. G., Jones, S., Olajide, O., Strayhorn, D., Hinderliter, A., & Orringer, E. P. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06110.x · Cited by 298 · cited 1×
“In contrast, other cross-sectional studies have reported a lower prevalence of pulmonary hypertension in patients on hydroxyurea therapy compared with those not taking the drug [2,10], and a recent pediatric series suggests that TRV may fall during hydroxyurea therapy [11].”
ResultN-Terminal Pro-Brain Natriuretic Peptide Levels and Risk of Death in Sickle Cell Disease
Machado, R. F., Anthi, A., Steinberg, M. H., Bonds, D., Sachdev, V., Kato, G. J., Taveira-DaSilva, A. M., Ballas, S. K., Blackwelder, W., Xu, X., et al. (2006) · JAMA · doi:10.1001/jama.296.3.310 · Cited by 197 · cited 8×
“Thus, hydroxyurea may be worth considering in SCD patients with Am J Hematol.”
BackgroundInfluentialSelf-citation
Cited by
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
Kato, G. J., Hebbel, R. P., Steinberg, M. H., & Gladwin, M. T. (2009) · American Journal of Hematology · doi:10.1002/ajh.21475 · Cited by 349
Self-citationKlings, E. S., Machado, R. F., Barst, R. J., Morris, C. R., Mubarak, K. K., Gordeuk, V. R., Kato, G. J., Ataga, K. I., Gibbs, J. S., Castro, O., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201401-0065st · Cited by 263
Self-citationHemodynamic Predictors of Mortality in Adults with Sickle Cell Disease
Mehari, A., Alam, S., Tian, X., Cuttica, M. J., Barnett, C. F., Miles, G., Xu, D., Seamon, C., Adams-Graves, P., Castro, O. L., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1222oc · Cited by 135
“Last, supportive care of SCD with hydroxyurea or chronic transfusion has been more aggressively promoted in the last decade, and anecdotal evidence indicates that in some cases this may lead to better control of pulmonary arterial pressures (39, 40).”
BackgroundSelf-citation
Metadata
- Authors
- Olnes, M., Chi, A., Haney, C., May, R., Minniti, C., Taylor, J., & Kato, G. J.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2009-06-17
- Volume
- 84
- Issue
- 8
- Pages
- 529-531
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W1989629828
- Cited by
- 45
- References
- 6
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. https://app.cochat.ai/papers/10.1002/ajh.21446
- The paper
- Olnes, M., Chi, A., Haney, C., May, R., Minniti, C., Taylor, J., & Kato, G. J. (2009). Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. American Journal of Hematology. https://doi.org/10.1002/ajh.21446
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.